0001415889-18-000013.txt : 20180104
0001415889-18-000013.hdr.sgml : 20180104
20180104182334
ACCESSION NUMBER: 0001415889-18-000013
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180102
FILED AS OF DATE: 20180104
DATE AS OF CHANGE: 20180104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brege Laura
CENTRAL INDEX KEY: 0001365619
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50768
FILM NUMBER: 18511502
MAIL ADDRESS:
STREET 1: C/O ONYX PHARMACEUTICALS, INC.
STREET 2: 2100 POWELL STREET
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001070494
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 061376651
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3611 VALLEY CENTRE DRIVE
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 858-558-2871
MAIL ADDRESS:
STREET 1: 3611 VALLEY CENTRE DRIVE
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
form4-01042018_030120.xml
X0306
4
2018-01-02
0001070494
ACADIA PHARMACEUTICALS INC
ACAD
0001365619
Brege Laura
3611 VALLEY CENTRE DRIVE, SUITE 300
SAN DIEGO
CA
92130
true
false
false
false
Common Stock
2018-01-02
4
M
0
15000
8.06
A
15000
D
Common Stock
2018-01-02
4
M
0
10000
8.49
A
25000
D
Common Stock
2018-01-02
4
S
0
25000
30.0617
D
0
D
Stock option (right to buy)
8.06
2018-01-02
4
M
0
15000
0
D
2018-04-30
Common Stock
15000
0
D
Stock option (right to buy)
8.49
2018-01-02
4
M
0
10000
0
D
2018-06-12
Common Stock
10000
0
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in October 2017.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.13 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following the date of grant of May 1, 2008.
25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following the date of grant of June 13, 2008.
/s/ Elizabeth Carter, Attorney-in-Fact
2018-01-04